Long‐term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high‐frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Long‐term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high‐frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study
Authors
Keywords
-
Journal
HEADACHE
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2021-07-26
DOI
10.1111/head.14194
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial
- (2021) Messoud Ashina et al. EUROPEAN JOURNAL OF NEUROLOGY
- Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study
- (2020) Stewart J Tepper et al. CEPHALALGIA
- Dopaminergic symptoms in migraine: A cross-sectional study on 1148 consecutive headache center-based patients
- (2020) Piero Barbanti et al. CEPHALALGIA
- One-year sustained efficacy of erenumab in episodic migraine
- (2020) Peter J. Goadsby et al. NEUROLOGY
- Erenumab does not alter cerebral hemodynamics and endothelial function in migraine without aura
- (2020) Claudia Altamura et al. CEPHALALGIA
- LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF FREMANEZUMAB IN MIGRAINE: A RANDOMIZED STUDY
- (2020) Peter J. Goadsby et al. NEUROLOGY
- Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension
- (2020) Richard B Lipton et al. CEPHALALGIA
- Erenumab in the prevention of high‐frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real‐life study
- (2020) Piero Barbanti et al. HEADACHE
- European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
- (2019) Simona Sacco et al. JOURNAL OF HEADACHE AND PAIN
- Real-world insights on the management of migraine patients: an Italian nationwide study
- (2019) Elio Agostoni et al. CURRENT MEDICAL RESEARCH AND OPINION
- Erenumab: A First-in-Class Monoclonal Antibody for Migraine Prevention
- (2019) Scott G. Garland et al. ANNALS OF PHARMACOTHERAPY
- Effects of Anti-Calcitonin Gene-Related Peptide for Migraines: A Systematic Review with Meta-Analysis of Randomized Clinical Trials
- (2019) I-Hsin Huang et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Trigeminal‐Targeted Treatments in Migraine: Is 60% the Magic Number?
- (2019) Piero Barbanti et al. HEADACHE
- Current and emerging evidence-based treatment options in chronic migraine: a narrative review
- (2019) Elio Clemente Agostoni et al. JOURNAL OF HEADACHE AND PAIN
- Mechanisms of migraine as a chronic evolutive condition
- (2019) Anna P. Andreou et al. JOURNAL OF HEADACHE AND PAIN
- Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition
- (2018) CEPHALALGIA
- Female sex hormones in men with migraine
- (2018) Willebrordus P.J. van Oosterhout et al. NEUROLOGY
- Pharmacologic Prevention of Migraine: A Narrative Review of the State of the Art in 2018
- (2018) Elizabeth Loder et al. HEADACHE
- A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine
- (2018) Angelo Camporeale et al. BMC Neurology
- Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial
- (2017) Stewart Tepper et al. LANCET NEUROLOGY
- A Controlled Trial of Erenumab for Episodic Migraine
- (2017) Peter J. Goadsby et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interictal burden attributable to episodic headache: findings from the Eurolight project
- (2016) Christian Lampl et al. JOURNAL OF HEADACHE AND PAIN
- Systematic Review of Migraine Prophylaxis Adherence and Persistence
- (2016) Zsolt Hepp et al. JOURNAL OF MANAGED CARE PHARMACY
- OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine
- (2015) Eva Cernuda-Morollón et al. PAIN
- Preventive Pharmacotherapy in Migraine
- (2013) Paul Rizzoli HEADACHE
- Cephalalgiaphobia as a feature of high-frequency migraine: a pilot study
- (2013) Giulia Giannini et al. JOURNAL OF HEADACHE AND PAIN
- Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine
- (2013) E. Cernuda-Morollon et al. NEUROLOGY
- Testosterone pellet implants and migraine headaches: A pilot study
- (2012) Rebecca Glaser et al. MATURITAS
- Understanding Migraine through the Lens of Maladaptive Stress Responses: A Model Disease of Allostatic Load
- (2012) David Borsook et al. NEURON
- CGRP receptor antagonism and migraine
- (2010) Lars Edvinsson et al. Neurotherapeutics
- Androgenic suppression of spreading depression in familial hemiplegic migraine type 1 mutant mice
- (2009) Katharina Eikermann-Haerter et al. ANNALS OF NEUROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now